sr 95531 has been researched along with neuropeptide y (13-36) in 1 studies
| Studies (sr 95531) | Trials (sr 95531) | Recent Studies (post-2010) (sr 95531) | Studies (neuropeptide y (13-36)) | Trials (neuropeptide y (13-36)) | Recent Studies (post-2010) (neuropeptide y (13-36)) |
|---|---|---|---|---|---|
| 610 | 0 | 209 | 76 | 0 | 6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kash, TL; Winder, DG | 1 |
1 other study(ies) available for sr 95531 and neuropeptide y (13-36)
| Article | Year |
|---|---|
Neuropeptide Y and corticotropin-releasing factor bi-directionally modulate inhibitory synaptic transmission in the bed nucleus of the stria terminalis.
Topics: Analysis of Variance; Aniline Compounds; Animals; Corticotropin-Releasing Hormone; Dose-Response Relationship, Radiation; Drug Interactions; Electric Stimulation; Excitatory Postsynaptic Potentials; GABA Antagonists; gamma-Aminobutyric Acid; In Vitro Techniques; Inhibitory Postsynaptic Potentials; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neurons; Neuropeptide Y; Patch-Clamp Techniques; Peptide Fragments; Pyridazines; Pyrimidines; Receptors, Corticotropin-Releasing Hormone; Septal Nuclei; Synaptic Transmission; Urocortins | 2006 |